Showing 2,301 - 2,320 results of 36,012 for search '2 Chainz~', query time: 4.44s Refine Results
  1. 2301

    Chemical Composition Characteristics and Source Apportionment of PM2.5 in Ceramic Industrial Base during Winter by Xiang Tu, Xiaozhen Fang, Hansun Fang, Changlin Ye, Zugen Liu, Xuehui Jia, Dan He, Jinliang Wang, Hong Huang, Changwei Zou, Chenglong Yu

    Published 2022-03-01
    “…Abstract The national architectural ceramic industrial center in east China is suffering from serious ambient fine particle pollution. …”
    Get full text
    Article
  2. 2302

    Protective potential of structural proteins of the SARS-CoV-2 virus in protecting against COVID-19 by Inna V. Dolzhikova, Daria M. Grousova, Ilya D. Zorkov, Anna A. Ilyukhina, Anna V. Kovyrshina, Olga V. Zubkova, Olga D. Popova, Tatiana A. Ozharovskaya, Denis I. Zrelkin, Daria M. Savina, Ekaterina G. Samokhvalova, Amir I. Tukhvatulin, Dmitry V. Shcheblyakov, Denis Yu. Logunov, Alexander L. Gintsburg

    Published 2024-12-01
    “…Due to the constant change in circulating variants of the SARS-CoV-2 virus, the decrease in the effectiveness of the vaccines with the original antigen composition against new variants of the virus and the continuing high incidence of COVID-19, it is necessary to continuously monitor the effectiveness of vaccines against new variants of the virus and promptly update the antigen composition of vaccines when a decrease in effectiveness is detected.…”
    Get full text
    Article
  3. 2303

    Pharmacoeconomics and Utilisation of Antidiabetic Medications among Type 2 Diabetes Mellitus Patients: A Longitudinal Study by Bikash Chandra Das, P Ansuman Abhisek, Deepak Choudhury, Suvendu Kumar Panda, Jayanti Prava Behera, Supriya Pradhan, Trupti Rekha Swain, Sasmita Mallick

    Published 2025-01-01
    “…Introduction: Patients with Type 2 Diabetes Mellitus (T2DM) typically require long-term treatment with antidiabetic medications, resulting in a significant financial burden on both the individual and the global economy. …”
    Get full text
    Article
  4. 2304

    Regulation of NK cell development, maturation, and antitumor responses by the nuclear receptor NR2F6 by Johannes Woelk, Florian Hornsteiner, Stephanie Aschauer-Wallner, Patrizia Stoitzner, Gottfried Baier, Natascha Hermann-Kleiter

    Published 2025-02-01
    “…Administration of exogenous IL-15 in vitro and as IL-15 complex in vivo can compensate for these deficits, promoting terminal maturation of NK cells in Nr2f6-deficient mice. Subsequent transcriptome analysis reveals significant changes in gene expression profiles of NK cells from IL-15 complex treated Nr2f6-deficient mice, with notable alterations in essential NK genes such as Klrg1, Prdm1, Stat5a, Zeb2, and Prf1. …”
    Get full text
    Article
  5. 2305

    Integrated Three-Dimensional Structural and Petrophysical Modeling for Assessment of CO2 Storage Potential in Gas Reservoir by Syed Yasir Ali Shah, Jiangfeng Du, Sayed Muhammad Iqbal, Linze Du, Umair Khan, Baoyi Zhang, Jingqiang Tan

    Published 2024-12-01
    “…Carbon dioxide (CO2) storage in oil and gas reservoirs is one of the most effective methods for enhancing hydrocarbon recovery efficiency and mitigating climate change by securely storing CO2. …”
    Get full text
    Article
  6. 2306

    Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer by Sara M Tolaney, Tianyu Li, Edward T Richardson, Judith Agudo, Elizabeth A Mittendorf, Beth Overmoyer, Eric P Winer, Adrienne G Waks, Tanya E Keenan, Nabihah Tayob, Gerburg M Wulf, Victoria Attaya, Leilani Anderson, Ian E Krop, Eliezer M Van Allen

    Published 2022-10-01
    “…Background Preclinical and clinical data support potential synergy between anti-HER2 therapy plus immune checkpoint blockade. The safety and tolerability of trastuzumab emtansine (T-DM1) combined with pembrolizumab is unknown.Methods This was a single-arm phase Ib trial (registration date January 26, 2017) of T-DM1 plus pembrolizumab in metastatic, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. …”
    Get full text
    Article
  7. 2307

    Machine learning and AVO class II workflow for hydrocarbon prospectivity in the Messinian offshore Nile Delta Egypt by Nadia Abd-Elfattah, Aia Dahroug, Manal El Kammar, Ramy Fahmy

    Published 2025-01-01
    “…The study area, covering 1850 km2, includes major structures such as the Rosetta fault and Nile Delta offshore anticline, with reservoirs consisting of layered sandstones and mudstones. …”
    Get full text
    Article
  8. 2308

    Expression of USP18 and IL2RA Is Increased in Individuals Receiving Latent Tuberculosis Treatment with Isoniazid by Eleane de Oyarzabal, Lourdes García-García, Claudia Rangel-Escareño, Leticia Ferreyra-Reyes, Lorena Orozco, María Teresa Herrera, Claudia Carranza, Eduardo Sada, Esmeralda Juárez, Alfredo Ponce-de-León, José Sifuentes-Osornio, Robert J. Wilkinson, Martha Torres

    Published 2019-01-01
    “…Conclusions. Changes in the profiles of USP18, IL2RA, IFNA, CCL4, and CXCL11 expressions during INH treatment in TST-positive individuals, regardless of IGRA status, are potential tools for monitoring latent tuberculosis treatment.…”
    Get full text
    Article
  9. 2309

    The Impact of Migraine on the Whole Life Course of Patients: Results from the OVERCOME (Japan) 2nd Study by Daisuke Danno, Shiho Suzuki, Tsubasa Takizawa, Ryotaro Ishii, Masayuki Hamakawa, Yoshinori Tanizawa, Satoshi Osaga, Mika Komori

    Published 2024-12-01
    “…The migraine group had mean (SD) 3.5 (5.2) MHDs; 24.2–56.7% had moderate-to-very severe disease burden per various PRO instruments. …”
    Get full text
    Article
  10. 2310

    Difference of SARS-CoV-2 infection and influence factors between people with and without HIV infection by Jianhui Yang, Esben Strodl, Dandan Zhang, Haibo Jiang, Kun Chu, Shiwen Tan, Zehao Ye, Hongbo Shi, Feng Tong, Weiqing Chen

    Published 2025-01-01
    “…In addition, we explored the risk factors associated with SARS-CoV-2 infection and the long nucleic acid conversion time among the two groups. …”
    Get full text
    Article
  11. 2311

    Associations of PM2.5 and its components with term preterm rupture of membranes: a retrospective study by Jiangxia Qin, Weiling Liu, Haidong Zou, Chong Zeng, Cifeng Gao, Weiqi Liu

    Published 2025-01-01
    “…Using 1:1 case matching, we included 1,216 TPROM cases and 1,216 controls. PM2.5 and its component concentrations were obtained from Tracking Air Pollution in China. …”
    Get full text
    Article
  12. 2312
  13. 2313

    Variations in Sources, Composition, and Exposure Risks of PM2.5 in both Pre-Heating and Heating Seasons by Dingyuan Yang, Zhiyong Li, Ziyuan Yue, Jixiang Liu, Zhen Zhai, Zelin Li, Minglei Gao, Ailian Hu, Wenjia Zhu, Ning Ding, Zhenxin Li, Songtao Guo, Xiangxue Wang, Lei Wang, Jihong Wei

    Published 2022-01-01
    “…Abstract “Clean Heating” (CH) was promoted in 2017 in north China. Nevertheless, CH impacts on PM2.5 chemical components, sources, and health risks in small cities remain unclear. …”
    Get full text
    Article
  14. 2314

    Thermal properties and non-bonded interactions in human PMP2 variants: A molecular dynamics study by Prabin Aryal, Jhulan Powrel

    Published 2025-01-01
    “…This disease is caused due to mutation in the human peripheral myelin protein 2 (PMP2) responsible for myelin formation and maintenance. …”
    Get full text
    Article
  15. 2315

    Thermal properties and non-bonded interactions in human PMP2 variants: A molecular dynamics study by Prabin Aryal, Jhulan Powrel

    Published 2025-01-01
    “…This disease is caused due to mutation in the human peripheral myelin protein 2 (PMP2) responsible for myelin formation and maintenance. …”
    Get full text
    Article
  16. 2316

    Argonaute2 and Argonaute4 Involved in the Pathogenesis of Kawasaki Disease via mRNA Expression Profiles by Zon-Min Lee, Hui-Chuan Chang, Shih-Feng Liu, Ying-Hsien Huang, Ho-Chang Kuo

    Published 2025-01-01
    “…We used the default value of the commercialized microarray tool Partek to perform an analysis of variance and determine any significant fold changes (KD1, KD3, HC, and FC individually). Results: The data revealed that the AGO2 and AGO4 genes displayed significant within-group differences with <i>p</i> = 0.034 and 0.007, respectively. …”
    Get full text
    Article
  17. 2317

    Dietary protein intake and PM2.5 on ovarian cancer survival: A prospective cohort study by He-Li Xu, Yi-Fan Wei, Qi Bao, Ya-Li Wang, Xiao-Ying Li, Dong-Hui Huang, Fang-Hua Liu, Yi-Zi Li, Yue-Yang Zhao, Xin-Xin Zhao, Qian Xiao, Song Gao, Ren-Jie Chen, Ling Ouyang, Xia Meng, Xue Qin, Ting-Ting Gong, Qi-Jun Wu

    Published 2025-02-01
    “…By assessing the relative excess risk due to interaction (RERI) arising from the interplay between PM2.5 exposure and dietary protein intake, we explored the additive interaction between the two. …”
    Get full text
    Article
  18. 2318

    Identification of Potential Type II Diabetes in a Chinese Population with a Sensitive Decision Tree Approach by Dongmei Pei, Chengpu Zhang, Yu Quan, Qiyong Guo

    Published 2019-01-01
    “…The accuracy, precision, recall, and area under the receiver operating characteristic curve (AUC) value for identifying potential diabetes were 94.2%, 94.0%, 94.2%, and 94.8%, respectively. The structure of the decision tree shows that age is the most significant feature. …”
    Get full text
    Article
  19. 2319

    Implementasi Algoritme Morus V2 untuk Pengamanan Data Pada Perangkat Bluetooth Low Energy by Diah Ratih Destyorini, Ari Kusyanti, Reza Andria Siregar

    Published 2022-12-01
    “…Pada penelitian ini algoritme MORUS V2 dipilih untuk mengamankan data dari serangan. …”
    Get full text
    Article
  20. 2320

    Pegilated interferon alpha 2b «Pegaltevir» chronic hepatitis C treatment (randomized clinical trial) by Marina V. Mayevskaya, Ye. N. Bessonova, P. O. Bogomolov, N. I. Geyvandova, K. V. Zhdanov, V. G. Morozov, V. D. Pasechnikov, I. Yu. Khomenko, A. V. Yagoda, V. T. Ivashkin

    Published 2018-08-01
    “…In HCV genotype 1 patients in Pegaltevir® treatment group SVR made 73,6%, in PegIntron® treatment group - 83,3%, p>0,1, for non-genotype 1 (2 and 3) - 92,9 and 81,3%, p>0,1. No significant differences between basic and control groups at analysis of paired liver biopsies for fibrosis stage reduction rate, absence of negative changes for fibrosis severity and proportion of patients with fibrosis progression were found. …”
    Get full text
    Article